Panagora Asset Management Inc. Purchases 15,814 Shares of LivaNova PLC $LIVN

Panagora Asset Management Inc. boosted its position in LivaNova PLC (NASDAQ:LIVN) by 6.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 255,687 shares of the company’s stock after acquiring an additional 15,814 shares during the quarter. Panagora Asset Management Inc. owned 0.47% of LivaNova worth $10,043,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. UMB Bank n.a. increased its stake in LivaNova by 340.5% in the first quarter. UMB Bank n.a. now owns 837 shares of the company’s stock valued at $33,000 after acquiring an additional 647 shares during the last quarter. CWM LLC grew its stake in shares of LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company’s stock valued at $34,000 after buying an additional 299 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of LivaNova by 415.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company’s stock valued at $58,000 after buying an additional 1,184 shares during the last quarter. Central Pacific Bank Trust Division grew its stake in shares of LivaNova by 7.0% during the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company’s stock valued at $173,000 after buying an additional 290 shares during the last quarter. Finally, Corton Capital Inc. bought a new position in shares of LivaNova during the fourth quarter valued at about $214,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Performance

Shares of LIVN opened at $56.37 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. LivaNova PLC has a one year low of $32.48 and a one year high of $57.35. The company has a 50-day simple moving average of $47.53 and a two-hundred day simple moving average of $43.29. The firm has a market capitalization of $3.08 billion, a PE ratio of -14.49 and a beta of 0.96.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The business had revenue of $352.50 million during the quarter, compared to analyst estimates of $332.20 million. During the same period last year, the business posted $0.93 earnings per share. LivaNova’s quarterly revenue was up 10.6% compared to the same quarter last year. On average, analysts anticipate that LivaNova PLC will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research note on Tuesday, May 13th. Robert W. Baird raised their price objective on LivaNova from $55.00 to $61.00 and gave the company an “outperform” rating in a research note on Thursday, May 8th. Wolfe Research raised LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective on the stock in a research note on Tuesday, May 20th. Barclays raised their price objective on LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Finally, Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, LivaNova currently has a consensus rating of “Buy” and a consensus target price of $59.71.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.